Chikungunya in the United States 2026
Chikungunya statistics in the US 2026 have become a genuine talking point this year for a reason that hasn’t occurred since 2019: a locally acquired case returned to a U.S. state. On October 14, 2025, the New York State Department of Health confirmed that a Nassau County resident on Long Island had contracted chikungunya without any recent travel history, marking the first locally acquired chikungunya case reported in any U.S. state or territory since 2019, and the first ever recorded in New York State specifically. According to the Centers for Disease Control and Prevention (CDC), the case was likely caused by a local Aedes albopictus mosquito that had previously bitten an infected traveler and then transmitted the virus onward to a new host — a textbook example of how local transmission cycles begin in regions that were previously considered low-risk.
This single case sits against a backdrop of significantly elevated global chikungunya activity heading into 2026. The CDC’s own surveillance data, reported through ArboNET (the national arboviral disease surveillance system), shows that 2025 was the highest year for U.S. travel-associated chikungunya cases since 2015, with 466 travel-associated cases recorded in U.S. states, alongside the single locally acquired case in New York. Globally, the World Health Organization reported 502,264 confirmed and suspected chikungunya cases between January 1 and December 10, 2025, including 186 deaths worldwide, and as of mid-2026, the CDC maintains active Level 2 Travel Health Notices for Bolivia, Mayotte, Suriname, Seychelles, and Mauritius — the widest simultaneous multi-country chikungunya travel warning since the virus’s major emergence in the Americas in 2014. This article compiles the most current, CDC-verified statistics on chikungunya cases, symptoms, diagnosis, and treatment in the United States for 2026.
Interesting Facts About Chikungunya in the US 2026
| Fact | Detail |
|---|---|
| Locally acquired US cases in 2025 | 1 case — Nassau County, Long Island, New York |
| Last prior locally acquired US case before 2025 | 2019 (in U.S. territories); 2015 in a U.S. state (Texas) |
| Travel-associated US state cases in 2025 | 466 cases — highest since 2015 |
| U.S. territory cases in 2025 (locally acquired) | 0 cases |
| U.S. territory cases in 2025 (travel-associated) | 0 cases |
| Global chikungunya cases (Jan 1–Dec 10, 2025) | 502,264 cases reported worldwide |
| Confirmed cases among the global 2025 total | 208,335 confirmed cases |
| Global chikungunya deaths in 2025 | 186 deaths worldwide |
| Active CDC Level 2 Travel Notices (as of mid-2026) | 5 countries/territories: Bolivia, Mayotte, Suriname, Seychelles, Mauritius |
| Countries reporting chikungunya activity in 2025 | 40 countries across the Americas, Africa, Asia, and Europe |
| Time from infected mosquito bite to symptom onset | 3–7 days |
| Share of infected people who develop symptoms | Most people infected will develop some symptoms |
| VIMKUNYA vaccine FDA approval | February 2025 |
| ACIP vaccine recommendation issued | April 2025 |
| VIMKUNYA seroresponse rate (ages 12–64, 3 weeks post-dose) | 98% |
| VIMKUNYA seroresponse rate (ages 65+, 3 weeks post-dose) | 87% |
| Réunion Island 2025 seroprevalence (population already exposed) | 66% (ranging from 58.1% to 74.3% by region) |
| Paraguay 2023 outbreak size (recent regional reference) | Over 160,000 suspected cases |
| Maximum attack rate in an active outbreak area | Up to 75% of the local population can be affected |
Source: CDC ArboNET Chikungunya Surveillance Data (current as of January 13, 2026, last reviewed February 24, 2026); World Health Organization Chikungunya Virus Disease Global Risk Assessment (2026); CDC Travel Health Notices (current as of June 2026); CDC Yellow Book, Chikungunya chapter (reviewed January 29, 2026); New York State Department of Health press release, October 14, 2025
The facts table above captures a pivotal shift in how chikungunya is being tracked and discussed in the United States heading into 2026. For nearly a decade, U.S. chikungunya statistics told a fairly stable story: a small, steady trickle of travel-associated cases each year, with zero local transmission since 2019. The October 2025 confirmation of a locally acquired case in Nassau County, Long Island, breaks that pattern in a way public health officials are watching closely, even as New York’s own Health Commissioner, Dr. James McDonald, noted at the time that “given the much colder nighttime temperatures, the current risk in New York is very low.” The case is a reminder that the Aedes albopictus mosquito, which is already established throughout large parts of the United States, including downstate New York, only needs to bite one infected traveler to potentially begin a new local transmission cycle.
The broader 2025 numbers reinforce why this single case matters: with 466 travel-associated cases reported in U.S. states — the highest figure recorded since the 895 cases seen in 2015 — and a striking 502,264 cases reported globally by the World Health Organization for the same year, the overall volume of circulating virus, and therefore the number of potentially infected travelers entering the U.S., has risen substantially. This context is precisely why the CDC currently maintains active travel notices for five separate countries and territories simultaneously — Bolivia, Mayotte, Suriname, Seychelles, and Mauritius — a multi-country alert footprint that public health researchers have described as the widest since chikungunya first arrived in the Americas in 2014. For Americans, the practical implication is straightforward: chikungunya risk is no longer confined to a handful of well-known endemic regions, and travelers to a widening list of countries should now factor the virus into their pre-trip health planning.
US Chikungunya Cases by Year 2026
US Chikungunya Cases Reported to ArboNET, 2014–2025 (Travel-Associated, States)
─────────────────────────────────────────────────────────────────────────────────
2014 │██████████████████████████░░ 2,799
2015 │█████████░░░░░░░░░░░░░░░░░░░░ 895
2016 │██░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 248
2017 │█░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 156
2018 │█░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 116
2019 │██░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 192
2020 │░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 33
2021 │░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 36
2022 │█░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 81
2023 │█░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 152
2024 │██░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 241
2025 │█████░░░░░░░░░░░░░░░░░░░░░░░░░ 466 ← highest since 2015
└────────────────────────────────────────
(Source: CDC ArboNET, data current as of Jan. 13, 2026)
| Year | US States — Locally Acquired | US States — Travel-Associated | US Territories — Locally Acquired | US Territories — Travel-Associated |
|---|---|---|---|---|
| 2014 | 12 | 2,799 | 4,659 | 51 |
| 2015 | 1 | 895 | 237 | 0 |
| 2016 | 0 | 248 | 180 | 1 |
| 2017 | 0 | 156 | 39 | 0 |
| 2018 | 0 | 116 | 8 | 0 |
| 2019 | 0 | 192 | 2 | 0 |
| 2020 | 0 | 33 | 0 | 0 |
| 2021 | 0 | 36 | 0 | 0 |
| 2022 | 0 | 81 | 0 | 0 |
| 2023 | 0 | 152 | 0 | 0 |
| 2024 | 0 | 241 | 0 | 0 |
| 2025 | 1 | 466 | 0 | 0 |
Source: CDC ArboNET Chikungunya Surveillance Data, “Chikungunya in the United States,” last updated February 24, 2026; 2025 figures preliminary and current as of January 13, 2026
This year-by-year breakdown is the single most important dataset for understanding chikungunya’s true trajectory in the United States, and it tells a story of dramatic early volatility followed by nearly a decade of quiet, low-level travel-associated transmission — until 2025. The 2014 figures remain the historic peak by an enormous margin, with 2,799 travel-associated cases in U.S. states and a staggering 4,659 locally acquired cases in U.S. territories, almost entirely attributable to Puerto Rico’s explosive first-wave outbreak during the virus’s initial arrival in the Americas. The rapid decline from 2,799 cases in 2014 to just 116 by 2018 reflects both the natural exhaustion of susceptible populations in affected Caribbean territories and improved mosquito control and surveillance infrastructure across the region.
What makes the 2025 figures stand out so clearly is the sustained climb that began in 2022: from a low of 33 cases in 2020 (a year heavily affected by reduced international travel during the COVID-19 pandemic), travel-associated cases in U.S. states climbed steadily — 81 in 2022, 152 in 2023, 241 in 2024, and then nearly doubling again to 466 in 2025. This is a three-year, near-continuous upward trend, and it directly mirrors the resurgence of global chikungunya activity documented by the World Health Organization across the same period, particularly the major outbreaks that began on Réunion Island in 2024 and subsequently spread across the broader Indian Ocean region and into parts of the Americas through 2025. The reappearance of a single locally acquired case in New York in 2025 — the first in a U.S. state since 2015 and the first in any U.S. jurisdiction since 2019 — is the clearest possible signal that rising travel-associated case counts can, under the right mosquito and climate conditions, translate into renewed local transmission risk.
Chikungunya Local Transmission Timeline in the US 2026
Key Local Transmission Milestones in US Chikungunya History
──────────────────────────────────────────────────────────────
2006-2013 │ ~28 travelers/year tested positive (no local spread)
2013 │ First local transmission identified in the Americas (Caribbean)
2014 │ First US local transmission: Florida (12 cases)
2015 │ Local transmission: Texas (1 case) — last US state case until 2025
2015 │ Chikungunya becomes nationally notifiable condition
2016-2024 │ ZERO locally acquired cases in any US state or territory
2025 │ First US state case in 6 years: Nassau County, Long Island, NY
└────────────────────────────────────────────────────────────
(Source: CDC chikungunya history; NY State DOH, Oct. 14, 2025)
| Milestone | Year | Detail |
|---|---|---|
| Pre-2006 baseline | Before 2006 | Chikungunya “rarely identified” in U.S. travelers |
| Average annual travel cases, 2006–2013 | 2006–2013 | ~28 people per year tested positive, all travel-related |
| First local transmission in the Americas | Late 2013 | Identified in Caribbean countries and territories |
| First US local transmission (state) | 2014 | Florida — 12 locally acquired cases |
| First US territory local transmission | 2014 | Puerto Rico, U.S. Virgin Islands — 4,659 cases |
| Nationally notifiable status established | 2015 | Standardized case reporting begins via ArboNET |
| Second/last prior US state local case | 2015 | Texas — 1 locally acquired case |
| Longest US “zero local transmission” stretch | 2016–2024 | 9 consecutive years, zero locally acquired cases nationwide |
| 2025 local transmission resumes | October 14, 2025 | Nassau County, Long Island, New York |
| Mosquito species responsible (NY case) | 2025 | Aedes albopictus (“Asian tiger mosquito”) |
Source: CDC, “Chikungunya in the United States” (last reviewed February 24, 2026); New York State Department of Health official press release (October 14, 2025); NETEC Public Health Context Briefing (December 16, 2025)
The transmission timeline makes clear just how unusual the 2025 New York case really is in the context of U.S. public health history. Following the initial 2014 wave of local transmission in Florida and the 2015 case in Texas, the United States experienced an extraordinary nine consecutive years — from 2016 through 2024 — with zero locally acquired chikungunya cases reported anywhere in the country, even as travel-associated cases continued at low but steady levels every single year. This nine-year stretch reflected a combination of factors: improved mosquito surveillance, the relatively low number of travel-associated cases arriving each year (often under 200), and favorable climate conditions in most years that limited the window during which local Aedes albopictus populations could pick up and retransmit the virus before cooler weather reduced mosquito activity.
The Nassau County case breaking this streak in October 2025 is significant precisely because it did not occur during peak summer mosquito season — investigators noted the affected individual began experiencing symptoms in August 2025, meaning transmission likely occurred during the warmer months when local mosquito populations were most active, with the case only confirmed and announced in October after laboratory testing was completed at the state’s Wadsworth Center. Importantly, New York health officials were explicit that three additional chikungunya cases reported in the state during 2025 were all travel-associated, underscoring that the locally acquired Nassau County case was an isolated event rather than the start of a sustained local outbreak. Still, public health researchers, including those writing in the American Society for Microbiology’s November 2025 analysis, have flagged the case as a meaningful signal: with established Aedes aegypti and Aedes albopictus populations now present throughout large portions of the United States, any infected traveler arriving in a region with active mosquito populations carries a real, if still low, risk of initiating a new local transmission cycle.
Chikungunya Symptoms & Risk Factors in the US 2026
Chikungunya Symptom Onset & Risk Timeline
──────────────────────────────────────────────────────────────
Mosquito bite (Day 0)
│
▼
Incubation period: 3–7 days
│
▼
Symptom onset ──► Fever + Joint Pain (most common)
│ │
│ ├─► Headache
│ ├─► Muscle pain
│ ├─► Joint swelling
│ └─► Rash
▼
Most patients improve within 1 week
│
└─► Joint pain may persist for MONTHS in some patients
(Source: CDC Symptoms, Diagnosis & Treatment, Nov. 19, 2025)
| Symptom / Risk Indicator | CDC-Verified Detail |
|---|---|
| Incubation period (bite to symptom onset) | 3–7 days |
| Most common symptoms | Fever and joint pain |
| Other reported symptoms | Headache, muscle pain, joint swelling, rash |
| Share of infected people who develop symptoms | Most people infected develop some symptoms |
| Typical recovery time | Within 1 week for most patients |
| Joint pain duration in severe cases | Can be severe and disabling; may persist for months |
| Risk of death from chikungunya | Rare |
| Higher-risk group: newborns | Infected around the time of birth |
| Higher-risk group: older adults | Age 65 years and older |
| Higher-risk group: chronic conditions | High blood pressure, diabetes, heart disease |
| Person-to-person transmission | Does not occur — spread only via mosquito bite |
| Infectious period in blood (for mosquito re-transmission) | First week of illness |
Source: CDC “Symptoms, Diagnosis, & Treatment,” Chikungunya Virus, last updated November 19, 2025
The CDC’s clinical guidance on chikungunya symptoms establishes a fairly consistent and well-documented disease pattern, even as case counts and locations shift year to year. The 3-to-7-day incubation period between an infected mosquito bite and symptom onset is a critical window for travelers returning from affected areas, since the CDC explicitly advises that infected individuals should prevent mosquito bites during their first week of illness, given that the virus remains present in the bloodstream during this period and can be picked up by a local mosquito, which can then transmit the virus to other people — precisely the mechanism believed responsible for the 2025 Nassau County case. The defining symptom combination of fever and joint pain, often accompanied by headache, muscle pain, joint swelling, or rash, distinguishes chikungunya clinically, although the CDC notes that healthcare providers should also test for similar viruses like dengue and Zika, since these mosquito-borne illnesses frequently circulate in the same geographic regions and can present with overlapping symptoms.
The risk stratification data is particularly important for higher-risk populations living in or traveling to affected areas. The CDC specifically identifies newborns infected around the time of birth, adults aged 65 and older, and people with chronic conditions such as high blood pressure, diabetes, or heart disease as groups facing meaningfully elevated risk of severe disease. While death from chikungunya remains rare — a reassurance echoed consistently across CDC materials — the persistence of joint pain for months in a meaningful subset of patients represents the disease’s most significant long-term burden. This chronic joint pain, sometimes severe enough to be disabling, is what distinguishes chikungunya from many other mosquito-borne illnesses and is a major reason the CDC and international health bodies, including the World Health Organization, continue to prioritize both surveillance and vaccination efforts even though the disease’s acute mortality risk remains low.
Chikungunya Diagnosis & Treatment Statistics in the US 2026
Chikungunya Treatment Decision Pathway (CDC Guidance)
──────────────────────────────────────────────────────────────
Symptoms appear (fever + joint pain)
│
▼
See healthcare provider ──► Report travel history
│
▼
Testing ordered (rules out dengue, Zika)
│
▼
No specific antiviral treatment exists
│
├─► Rest
├─► Fluids
├─► Acetaminophen/paracetamol (fever & pain) ✓ SAFE
└─► AVOID aspirin/NSAIDs (e.g. ibuprofen) ✗ UNTIL dengue ruled out
(Source: CDC Treatment guidance, Nov. 19, 2025)
| Diagnosis & Treatment Indicator | CDC-Verified Guidance |
|---|---|
| Specific antiviral medicines available | None — no specific treatment exists for chikungunya |
| Recommended first-line symptom relief | Rest, fluids, over-the-counter pain medicines |
| Safe fever/pain medication | Acetaminophen or paracetamol |
| Medication to avoid until dengue is ruled out | Aspirin and NSAIDs (e.g., ibuprofen) — bleeding risk |
| Diagnostic tests typically ordered | Tests for chikungunya and similar viruses (dengue, Zika) |
| Key information to share with provider | When and where you traveled |
| Mosquito bite prevention period post-infection | First week of illness (viremic period) |
| VIMKUNYA vaccine availability in US | Available as of 2025–2026 |
| VIMKUNYA vaccine type | Virus-like particle (VLP) — not a live or weakened virus |
| VIMKUNYA approved age range | 12 years and older |
| VIMKUNYA dosing | Single dose, 0.8 mL, intramuscular |
Source: CDC “Symptoms, Diagnosis, & Treatment” (November 19, 2025); CDC “Chikungunya Vaccine” page (last updated January 23, 2026); Global Biodefense vaccine clinical data summary (April 16, 2026)
The treatment statistics for chikungunya remain unchanged in one fundamental respect: as of 2026, there are still no medicines that specifically treat the chikungunya virus itself. The CDC’s guidance is consistent and direct — management is entirely supportive, centered on rest, adequate fluids, and over-the-counter pain relief, specifically acetaminophen or paracetamol to manage fever and joint pain. The single most important safety instruction in the CDC’s treatment guidance is to avoid aspirin and NSAIDs such as ibuprofen until dengue infection has been ruled out, since these medications increase bleeding risk in patients who may actually have dengue rather than, or in addition to, chikungunya — a critical distinction given how clinically similar the two mosquito-borne illnesses can appear in their early stages.
The most significant treatment-adjacent development for 2026 is the continued rollout of VIMKUNYA, the virus-like particle chikungunya vaccine manufactured by Bavarian Nordic, which received FDA approval in February 2025 and an official Advisory Committee on Immunization Practices (ACIP) recommendation in April 2025. Clinical trial data show the vaccine achieves a 98% seroresponse rate in people aged 12 to 64 at three weeks post-vaccination, a figure that declines somewhat to 85% by six months, while adults 65 and older show a 87% response rate at three weeks, declining to 76% at six months — data that directly informs the CDC’s current recommendation that the vaccine be specifically considered for travelers visiting active outbreak areas, laboratory workers at risk of exposure, and those planning extended stays of six months or more in regions with elevated chikungunya risk. With five countries currently under active CDC travel notices and global case counts running into the hundreds of thousands annually, the single-dose VIMKUNYA vaccine represents the most significant new tool added to America’s chikungunya prevention strategy since the disease first arrived in the Western Hemisphere in 2013.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
